RESUMO
Two hundred fifty consecutive patients underwent coronary stenting and received a 2-week course of clopidogrel (75 mg orally each day after a loading dose of 150 mg) and aspirin. There was 1 (0.4%) in-hospital death, 1 (0.4%) acute stent thrombosis, and 2 (0.8%) subacute stent thromboses. There were no Q-wave myocardial infarctions, vascular complications, or repeat interventions at 30-day follow-up.
Assuntos
Angioplastia Coronária com Balão , Aspirina/administração & dosagem , Doença das Coronárias/terapia , Inibidores da Agregação Plaquetária/administração & dosagem , Stents , Ticlopidina/análogos & derivados , Idoso , Aspirina/efeitos adversos , Clopidogrel , Terapia Combinada , Doença das Coronárias/mortalidade , Trombose Coronária/mortalidade , Trombose Coronária/terapia , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Feminino , Mortalidade Hospitalar , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/mortalidade , Infarto do Miocárdio/terapia , Inibidores da Agregação Plaquetária/efeitos adversos , Recidiva , Ticlopidina/administração & dosagem , Ticlopidina/efeitos adversos , Resultado do TratamentoRESUMO
Interventional cardiology has undergone exciting changes since the first percutaneous transluminal coro-_ nary angioplasty was performed by Andreas Gruentzig in 1977.' Over the last several years, a variety of techniques have been developed which provide the interventional cardiologist with a range of options to treat coronary stenoses. In addition, the indications for intervention have radically changed since the original work by Gruentzig, who limited treatment to patients with a single focal stenosis in a large vessel. Advances in balloon angioplasty, as well as the development of new techniques such as directional atherectomy, laser angioplasty, rotational atherectomy, extraction atherectomy, and now intracoronary stents have given the interventional cardiologist the ability to treat multivessel disease, increasingly complex lesions, and less stable patients."
RESUMO
By using 2 monoclonal antibodies, we developed a solid-phase 2-site immunoradiometric assay for measuring human IgG4. The measuring range (0.05-20 micrograms/ml) covered more than 2 orders of magnitude. The sensitivity level should make this assay especially useful when IgG4 concentrations are too low to be detected by conventional methods.
